Evidence map›Paper›PMID 42291749›Full record

ArticleNeuro-oncology advances

Association between time to surgery and survival in patients with initially diagnosed WHO 2021 grade 4 gliomas.

Haruka Kanamitsu, Eiichi Ishikawa, Shunichiro Miki, Narushi Sugii, Masahide Matsuda

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haruka KanamitsuDepartment of Neurosurgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Eiichi IshikawaDepartment of Neurosurgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.ORCID https://orcid.org/0000-0001-9224-9767
Shunichiro MikiDepartment of Neurosurgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Narushi SugiiDepartment of Neurosurgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Masahide MatsudaDepartment of Neurosurgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastoma (GBM) and other WHO 2021 grade 4 gliomas are highly aggressive tumors treated with maximal safe resection followed by chemoradiation. Although these tumors grow rapidly, the optimal timing of surgery remains unclear. This study evaluated whether time to surgery (TTS), defined as the interval from first admission to surgery, affects prognosis in patients with grade 4 glioma. Methods: A total of 219 patients with grade 4 glioma were divided into 4 TTS groups (≤ 3 days, 4-7 days, 8-14 days, ≥ 15 days). Clinical data, including age, sex, tumor location, preoperative and postoperative Karnofsky Performance Status (KPS), KPS at discharge, time from hospitalization to surgery, and extent of resection (EOR), and other various factors, were collected from electronic medical records. Results: Patients who underwent surgery within 3 days had significantly lower preoperative KPS, whereas longer TTS was associated with higher KPS. Overall survival slightly longer in the group with longer TTS. However, among patients who achieved EOR ≥ 90%, TTS showed no association with survival. Multivariate analysis identified the following independent predictors of better prognosis: higher postoperative KPS, non-GBM histology, achievement of EOR ≥ 90%. TTS itself was not a prognostic factor. Conclusions: While urgent surgery is necessary for patients with rapid neurological deterioration, it is important to plan surgery at an appropriate time that allows for preservation of KPS and achievement of maximal safe resection.

Indexed as

doubling timehigh-grade gliomamaximal safe resectiontime to surgery

Identifiers

PMID42291749
PMCPMC13264394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.